预防性颅脑照射在早期小细胞肺癌术后患者中的系统评价与荟萃分析
该系统评价与荟萃分析评估了预防性颅脑照射(PCI)在术后早期小细胞肺癌(SCLC)患者中的疗效。共纳入13项回顾性研究、3530例术后SCLC患者(880例接受PCI)。结果显示PCI显著改善总生存(HR 0.66,95%CI 0.58-0.74,p<0.001)和脑转移无生存(HR 0.42,95%CI 0.29-0.60,p<0.001),但pN0患者总生存获益不显著(HR 0.85,95%CI 0.65-1.10,p=0.22),pN+患者获益显著(HR 0.52,95%CI 0.41-0.66,p<0.001)。
要点
- PCI显著改善术后早期SCLC患者的总生存和脑转移无生存。
- pN+患者从PCI中获得显著总生存获益。
- pN0患者未观察到显著的总生存获益。
核心结论
- PCI与术后早期SCLC患者总生存和脑转移无生存的显著改善相关。
- PCI的获益在pN+患者中尤为明显,而pN0患者未获得显著总生存获益。
- 研究结果支持根据淋巴结状态选择性使用PCI以优化术后SCLC患者的治疗结局。
研究设计与样本
- 通过PubMed、Cochrane和Embase数据库检索相关文献进行系统评价与荟萃分析。
- 共纳入13项回顾性研究,涵盖3530例术后SCLC患者,其中880例接受PCI治疗。
- 分析总体人群、pN0患者和pN+患者的总生存合并风险比(HR),以及全部患者的脑转移无生存合并HR,并进行敏感性分析验证结果稳定性。
主要发现
- 在总体患者人群中,PCI较非PCI组显著改善总生存(HR 0.66,95%CI 0.58-0.74,p<0.001)。
- pN0患者接受PCI未显示显著总生存获益(HR 0.85,95%CI 0.65-1.10,p=0.22)。
- pN+患者接受PCI显示显著总生存改善(HR 0.52,95%CI 0.41-0.66,p<0.001)。
- PCI显著改善全部患者的脑转移无生存(HR 0.42,95%CI 0.29-0.60,p<0.001)。
- 敏感性分析证实上述结果的稳定性。
临床怎么用
- 对于术后早期SCLC患者,可根据淋巴结状态选择性考虑PCI:pN+患者可能获益更明显,pN0患者需权衡获益与风险。
局限性
- 纳入研究均为回顾性研究,可能存在选择偏倚等混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of prophylactic cranial irradiation (PCI) in early stage small cell lung cancer (SCLC) patients post-surgery remains controversial. This meta-analysis aimed to evaluate the efficacy of PCI in resected early stage SCLC patients. METHODS: Relevant literature was reviewed through PubMed, Cochrane, and Embase databases. The pooled hazard ratios (HRs) for overall survival (OS) were analyzed for the overall population, as well as for pathologically node-negative (pN0) and pathologically node-positive (pN+) patients. We also assessed the pooled HRs for brain metastasis-free survival (BMFS) in all patients. Sensitivity analyses were conducted to validate these results. RESULTS: A total of 13 retrospective studies were included, encompassing 3,530 postoperative SCLC patients, of whom 880 received PCI treatment. In the overall patient population, PCI significantly improved OS compared to non-PCI group (HR: 0.66, 95% CI 0.58-0.74, p < 0.001). For pN0 patients, there was no significant OS benefit from PCI (HR: 0.85, 95% CI 0.65-1.10, p = 0.22). In contrast, pN + patients showed a significant OS improvement with PCI (HR: 0.52, 95% CI 0.41-0.66, p < 0.001). Furthermore, PCI significantly improved BMFS in all patients (HR: 0.42, 95% CI 0.29-0.60, p < 0.001). Sensitivity analyses confirmed the stability of these results. CONCLUSIONS: PCI was associated with a significant improvement in OS and BMFS in resected early stage SCLC patients. The benefits of PCI were particularly pronounced in pN + patients, whereas pN0 patients did not experience a significant OS benefit. These findings supported the selective use of PCI based on nodal status to optimize treatment outcomes in postoperative SCLC patients.
引用
- Yuan Z, Tao D, Yang D, et al. Prophylactic cranial irradiation in resected early stage small cell lung cancer: an updated systematic review and meta-analysis. Radiat Oncol. 2025. PMID: 40394671. doi:10.1186/s13014-025-02644-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。